Author:
Li Zhi,Zhao Can,He Ge,Wang Yujie,Wang Yang,Ma Xiaodong
Subject
Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry
Reference39 articles.
1. Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective;Garces;J Med Chem,2019
2. Evolution of PI3Kgamma and delta Inhibitors for Inflammatory and Autoimmune Diseases;Perry;J Med Chem,2019
3. Structurally novel PI3Kdelta/gamma dual inhibitors characterized by a seven-membered spirocyclic spacer: The SARs investigation and PK evaluation;Tao;Eur J Med Chem,2020
4. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma, Clinical cancer research : an official journal of the American Association for;Yang;Cancer Res,2015
5. Duvelisib, a novel oral dual inhibitor of PI3K-delta, gamma, is clinically active in advanced hematologic malignancies;Flinn;Blood,2018
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献